Page 22 - Update on Management of Renal Cell Carcinoma
P. 22
CheckMate 214: Baseline Characteristics
IMDC intermediate/
poor risk Intention to treat
Characteristics
NIVO + IPI SUN NIVO + IPI SUN
N = 425 N = 422 N = 550 N = 546
Median age, years 62 61 62 62
Male, % 74 71 75 72
IMDC prognostic score, %
Favorable (0) 0 0 23 23
Intermediate (1–2) 79 79 61 61
Poor (3–6) 21 21 17 16
Region, %
USA 26 26 28 28
Canada/Europe 35 35 37 36
Rest of the world 39 39 35 36
Quantifiable tumor PD-L1 expression, % n = 384 n = 392 n = 499 n = 503
<1% 74 71 77 75
≥1% 26 29 23 25
IMDC, International Metastatic RCC Database Consortium; IPI: ipilimumab; IV: intravenously; KPS, Karnofsky performance status; NIVO: nivolumab; PD-L1:
programmed death-ligand 1; Q2W, every 2 weeks; Q3W, every 3 weeks; RCC: renal cell carcinoma; SUN: sunitinib
22 Motzer RJ, et al. N Engl J Med 2018; 378(14):1277-90.
